| 摘要 |
1. Pharmaceutical composition, containing 3-(2,2,2-trimethylhydrazinium)propionate and angiotensin converting enzyme (ACE) inhibitor. 2. Pharmaceutical composition, according to Claim 1, where said ACE inhibitor is (S)-1-{N-1-(ethoxycarbonyl)-3-phenylpropyl-L-alanyl}-L proline or Enalapril. 3. Pharmaceutical composition, according to Claim 2, where the proportion of said active substances 3-(2,2,2-trimethyldrazinium) propionate dihydrate and (S)-1-{N-1-(ethoxycarbonyl)-3-phenylpropyl-L-alanyl}-L proline is within the range from 5:1 to 15:1, advisable from 8:1 to 12:1. 4. Use of the pharmaceutical composition according to any of the above Claims, for manufacturing of medicament providing for treatment of cardiovascular diseases.
|
